Overview and Scope
The ovarian cancer drugs refer to cancer drugs to treat ovarian cancer. Ovarian cancer is caused due to abnormal growth of cells in the ovary. This industry includes establishments that produce drugs used in chemotherapy, radiation, and surgery for treating ovarian cancer. The ovarian cancer drugs include Doxorubicin Hydrochloride Liposome, Evacet (Doxorubicin Hydrochloride Liposome), Cytoxan (Cyclophosphamide), Paraplat (Carboplatin), Taxol (Paclitaxel), Neosar (Cyclophosphamide) and others.
Sizing and Forecast
The ovarian cancer drugs market size has grown rapidly in recent years. It will grow from $4.48 billion in 2023 to $5.16 billion in 2024 at a compound annual growth rate (CAGR) of 15.0%. The growth in the historic period can be attributed to rising incidences of ovarian cancer, a rise of new medications and therapies, an increase in government initiatives for ovarian cancer treatment and increased healthcare expenditure.
The ovarian cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $8.94 billion in 2028 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to increasing geriatric population and an increase in pharmaceutical r&d expenditure. Major trends in the forecast period include aunching antibody-drug conjugates, partnerships and collaborations to improve revenues and product offerings, and focus on implanted drug factories for ovarian cancer.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/ovarian-cancer-drugs-global-market-report
Segmentation & Regional Insights
The ovarian cancer drugs market covered in this report is segmented –
1) By Tumor Type: Epithelial Ovarian Cancer, Germ Cell Ovarian Cancer, Stromal Cell Ovarian Cancer
2) By Drug Type: Alkylating Agents, Mitotic Inhibitors, VEGF/VEGFR inhibitors, PARP inhibitors, Other Drug Types
3) By Distribution Channel: Hospital Pharmacies, Drug Stores, Other Distribution Channels
North America was the largest region in the ovarian cancer drugs market in 2023. Middle East is expected to be the fastest-growing region in the global ovarian cancer drugs market share during the forecast period. The regions covered in the ovarian cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2593&type=smp
Major Driver Impacting Market Growth
The rising incidence of ovarian cancer is driving the ovarian cancer drugs market. Furthermore, ovarian cancer is recorded to be the eighth most commonly occurring cancer in women and the 18th most commonly occurring cancer across the globe. For instance, in 2023, according to the Ovarian Cancer Statistics, published by the American Cancer Society, a US-based government organization, about 19,710 new cancer cases and 13,270 deaths were expected in the USA . Thus, the increasing incidence of ovarian cancer cases across the globe drives the growth of the ovarian cancer drugs market.
Key Industry Players
Major companies operating in the ovarian cancer drugs market report are AstraZeneca plc, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Amgen Inc, Bristol-Myers Squibb Company, Clovis Oncology, Pfizer, Inc., Novartis AG, Pharma Mar SA, Vivesto, BDR Pharmaceutical, GLS Pharma, Eisai Co., Ltd., Denovo Biopharma, Jiangsu Hengrui Medicine, BeiGene, Innovent Biologics, Zai Lab , EUSA Pharma, Recordati ,, NEUCA, Farmacol, Polska Grupa Farmaceutyczna, Polpharma, TZMO, Msd Sanofi, Gilead Sciences , Johnson & Johnson, Merck & Co, AbbVie Inc, Aa Pharma In, Aaladin Superior Cleaning Systems Ltd, Accel Pharma Inc, EMS Pharma, Eurofarma, Neo Química, Mantecorp Farmasa , Abbott Laboratories Bayer , Laboratorio Elea Phoenix , Laboratorios Ac Farma , Teva , Monte Verde, Gador, Spimaco, Tabuk Pharmaceuticals, Jamjoom Pharma, Abcon International L.L.C., Adcan Pharma ,, Regal Pharmaceuticals Limited
The ovarian cancer drugs market report table of contents includes:
1. Executive Summary
2. Ovarian Cancer Drugs Market Characteristics
3. Ovarian Cancer Drugs Market Trends And Strategies
4. Ovarian Cancer Drugs Market – Macro Economic Scenario
5. Global Ovarian Cancer Drugs Market Size and Growth
………………………………
32. Global Ovarian Cancer Drugs Market Competitive Benchmarking
33. Global Ovarian Cancer Drugs Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Ovarian Cancer Drugs Market
35. Ovarian Cancer Drugs Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
